Reduction of the cost associated with exacerbations after treatment with nebulized sodium colistimethate (Promixin®) in patients with bronchiectasis (BQ) and chronic bronchial infection (CBI) with Pseudomonas aeruginosa (PsA).

E. Garcia Cortacero (Granada, Spain)

Source: International Congress 2017 – Clinical update on bronchiectasis and nontuberculous mycobacteria (NTM) infections

Session: Clinical update on bronchiectasis and nontuberculous mycobacteria (NTM) infections
Session type: Oral Presentation
Number: 1970

Disease area: Airway diseases

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
E. Garcia Cortacero (Granada, Spain). Reduction of the cost associated with exacerbations after treatment with nebulized sodium colistimethate (Promixin®) in patients with bronchiectasis (BQ) and chronic bronchial infection (CBI) with Pseudomonas aeruginosa (PsA).. 1970

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

Effectiveness and adherence to treatment with nebulized colistimethate sodium (Promixin®) in non-cystic fibrosis bronchiectasis colonized by pseudomonas aeruginosa (PsA) Source: International Congress 2015 – Bronchiectasis and NTM infections: clinical aspects and research outlook Year: 2015
Late Breaking Abstract - Reduction in frequency of pulmonary exacerbations (PE) with inhaled ARD-3150 in non-cystic fibrosis bronchiectasis (NCFB) patients is independent of Pseudomonas aeruginosa (PA) susceptibility at baseline Source: International Congress 2017 – Update on community acquired pneumonia Year: 2017
Effect of prior year pulmonary exacerbation (PE) frequency on response to ARD-3150 in patients with non-cystic fibrosis bronchiectasis (NCFB) chronically infected with Pseudomonas aeruginosa (PA) Source: International Congress 2018 – Improving the quality of life of patients with bronchiectasis Year: 2018
The difference between surfactant protein D (SPD) and C-reactive protein (CRP) levels in patients (pts) with chronic obstructive pulmonary disease acute exacerbations (AE COPD) and community acquired pneumonia (CAP) Source: International Congress 2014 – Clinical presentations Year: 2014
Surfactant protein D (SPD) like marker of effectiveness in patients (pts) with acute exacerbations (AE) of COPD ofphosphatidylcholine treatment outcomes Source: International Congress 2015 – Different data in COPD Year: 2015
Baseline profiles of subjects randomised in RESPIRE 2 trial of ciprofloxacin dry powder for inhalation (DPI) in non-CF bronchiectasis (NCFB) by pathogen and prior exacerbation rate Source: International Congress 2016 – Possible phenotypes of bronchiectasis and exacerbations Year: 2016
Short and long-term outcomes of moxifloxacin (MXF) compared to standard antibiotic treatment (STD) in acute exacerbations of chronic bronchitis (AECB): The MOSAIC study Source: Eur Respir J 2003; 22: Suppl. 45, 566s Year: 2003
Dual release ciprofloxacin for inhalation (DRCFI) reduces sputum pseudomonas aeruginosa (Pa) density and delays time to infective pulmonary exacerbation in non-cystic fibrosis (CF) bronchiectasis (BE) Source: Annual Congress 2011 - Advances in antibiotic therapy of non-cystic fibrosis bronchiectasis Year: 2011
Pseudomonas aeruginosa and antibiotic resistance in acute exacerbations of COPD (AECOPD) Source: Annual Congress 2009 - Respiratory infection caused by Pseudomonas aeruginosa Year: 2009
Robustness of assessment of pulmonary endpoints in phase 3 trials with ARD-3150 in non-cystic fibrosis bronchiectasis (NCFB) patients with chronic Pseudomonas aeruginosa (PA) infections Source: International Congress 2018 – Improving the quality of life of patients with bronchiectasis Year: 2018
Efficacy of azithromycin vs. ciprofloxacin in the treatment of patients with acute bacterial exacerbations of chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2002; 20: Suppl. 38, 544s Year: 2002
A randomised comparison of two tobramycin formulations in cystic fibrosis (CF) patients with chronic pseudomonas aeruginosa (PA) infection for pharmacokinetic and therapeutic equivalence Source: Annual Congress 2013 –Cystic fibrosis: basic and applied science Year: 2013
Plasma surfactant protein D (SP-D) in patients (pts) with stable (S) COPD and during COPD acute exacerbation (AE) Source: Annual Congress 2013 –COPD biomarkers Year: 2013
Efficacy and tolerability of budesonide/formoterol (B/F) added to tiotropium (T) vs T alone in East-Asian patients (pts) with severe/very severe chronic obstructive pulmonary disease (COPD) Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014
Indacaterol/glycopyrronium (IND/GLY) reduces exacerbation and improves lung function versus salmeterol/fluticasone (SFC) in patients with and without prior ICS use: The FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016
Severe exacerbations of chronic obstructive pulmonary disease (COPD) due to Pseudomonas aeruginosa: resistance to common antibiotics Source: Eur Respir J 2001; 18: Suppl. 33, 540s Year: 2001
Chlamydia pneumonia (CP), Mycoplasma pneumonia (MP) and virus antibody titres in acute exacerbations of asthma (BA) and chronic bronchitis (COPD) Source: Eur Respir J 2001; 18: Suppl. 33, 234s Year: 2001
Umeclidinium/vilanterol (UMEC/VI) once daily (OD) vs fluticasone/salmeterol combination (FSC) twice daily (BD) in patients with moderate-to-severe COPD and infrequent COPD exacerbations Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014
Efficacy of administration of 0.02% solution of decamethoxine via nebulizer in patients with infectious exacerbations of COPD Source: Annual Congress 2013 –COPD treatment Year: 2013
Influence of tiotropium bromide (TB) and carbocysteine (C) on mucociliary clearance (MCC) in patients with COPD Source: Annual Congress 2012 - COPD treatment and varia Year: 2012